Sign up for our eNewsletter
[f] [t] [in] [blog]
+
[scroll down]

Let’s launch new technologies together.

Exciting opportunities abound.

.

Investment Philosophy

Hoping to secure venture capital for your startup? Here’s our approach:

Stage We actively seek pre-seed, seed and early-stage (Series A) investments.
Amount Our typical investments range from $500K to $1M.
Sectors We primarily invest in software and IT, bioscience, clean tech, digital media and technologies important to advanced manufacturing such as photonics and advanced materials.
Geography We invest in companies headquartered in Connecticut or those willing to move here. 
Approach We value capital-efficient business models, proper governance and advisors (including a quality board of directors), experienced management teams, and milestone achievement to attract the next level of capital investment at an increased valuation.
Partnership Once we invest in your company, we become a true partner in your growth, offering strategic advice, connections and introductions, marketing and public relations support, educational resources and much more. Just ask any of the more than 100 companies we’ve invested in since inception.

Read more about our investment philosophy here.

Looking for angel investors? Learn more about the Angel Investor Tax Credit.

Looking for a savvy co-investment partner? It’s time you got to know Connecticut Innovations. Contact us today.

.

Our Portfolio

BioscienceMedical DevicesInformation TechnologyClean TechAdvanced Manufacturing

We currently have an array of exciting and innovative startups in our portfolio. Check them out by category of interest.

View portfolio

.

Successful Exits

EXITS

CI is proud to have supported dozens of exciting technology companies. Their notable exits not only thrilled us, but also enabled us to reinvest our returns into other ventures we think are just as promising.

View all exits

.

Case Studies

< >
[image]

According to the World Health Organization, tuberculosis is the second greatest killer worldwide due to a singular infectious agent (a bacterium called Mycobacterium tuberculosis).

View case studies

.

Venture Team

< >

Meet the team